AGC Biologics vs Wacker Biotech: CDMO Comparison
How does AGC Biologics compare to Wacker Biotech for Recombinant Proteins manufacturing?
As of Oct 2026, AGC Biologics: 4 FDA inspections (including 1 NAI, 3 VAI and 0 OAI), 27 EMA/MHRA GMP certificates. Signal Score 79.9. Wacker Biotech: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 13 EMA/MHRA GMP certificates. Signal Score 82.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of AGC Biologics and Wacker Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- AGC Biologics has more FDA inspections on record (4 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- AGC Biologics has materially broader EMA GMP coverage (27 active certificates vs 13) — stronger EU footprint.
On a 13-modality CDMO landscape, both AGC Biologics and Wacker Biotech qualify as Recombinant Proteins manufacturers; Wacker Biotech carries the higher composite Signal Score for Recombinant Proteins programs in this comparison.
What to evaluate for Recombinant Proteins programs
Both AGC Biologics and Wacker Biotech qualify as Recombinant Proteins CDMOs. When choosing between them for Recombinant Proteins programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.
Frequently asked: AGC Biologics vs Wacker Biotech
How does AGC Biologics compare to Wacker Biotech for Recombinant Proteins manufacturing?
On CDMO Signal's composite Signal Score, AGC Biologics is 80/100 and Wacker Biotech is 83/100; AGC Biologics has 4 FDA inspections on record vs 1 for Wacker Biotech; European coverage is 27 active EMA+MHRA certificates for AGC Biologics vs 13 for Wacker Biotech. Both are tracked in the CDMO Signal directory as Recombinant Proteins CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, AGC Biologics or Wacker Biotech?
Both AGC Biologics and Wacker Biotech maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. AGC Biologics has 4 FDA inspections on record; Wacker Biotech has 1.
How do AGC Biologics and Wacker Biotech compare on European GMP coverage?
AGC Biologics holds 27 active EMA GMP certificates and 0 MHRA / UK certificates. Wacker Biotech holds 13 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — AGC Biologics or Wacker Biotech?
AGC Biologics is matched to 2 ClinicalTrials.gov records as a manufacturing partner; Wacker Biotech is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Recombinant Proteins manufacturing — AGC Biologics or Wacker Biotech?
Both AGC Biologics and Wacker Biotech are tagged as Recombinant Proteins CDMOs in our directory, so both are credible options for Recombinant Proteins programs. The most important differentiator for Recombinant Proteins selection is typically expression host & scale: Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target. Review each CDMO's profile and inspection record before shortlisting.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →